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MEETING REPORT
Perspectives in melanoma: meeting report 
from the Melanoma Bridge (November 29th–1 
December 1st, 2018, Naples, Italy)
Paolo A. Ascierto1* , Sanjiv S. Agarwala2, Gerardo Botti3, Alfredo Budillon4, Michael A. Davies5, 
Reinhard Dummer6, Marc Ernstoff7, Soldano Ferrone8, Silvia Formenti9, Thomas F. Gajewski10, Claus Garbe11, 
Omid Hamid12, Roger S. Lo13, Jason J. Luke14, Oliver Michielin15, Giuseppe Palmieri16, Laurence Zitvogel17, 
Francesco M. Marincola18, Giuseppe Masucci19, Corrado Caracò20, Magdalena Thurin21* and Igor Puzanov22
Abstract 
Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic 
therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies 
have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but 
they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to 
therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker 
platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. 
There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with 
response in patients with melanoma and other cancers they have yet to be fully characterized and implemented 
clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in mela-
noma have led to the use of genome sequencing and gene expression for development of multi-marker assays that 
show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, 
melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, 
either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical 
studies is to achieve incremental improvements through the development and identification of optimal treatment 
regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of 
biomarkers to improve immune response. These and other topics in the management of melanoma were the focus 
of discussions at the fourth Melanoma Bridge meeting (November 29th–December 1st, 2018, Naples, Italy), which is 
summarised in this report.
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Introduction
Significant improvements in melanoma diagnosis, prog-
nosis and treatment have been achieved over the past 
decade. Improved insight into the genetic evolution of 
melanomas from their cells of origin through precursor 
lesion offers opportunities for improved diagnosis, ear-
lier detection of lesions at increased risk of progression 
and selective intervention at an earlier stage. Recently, 
new therapeutic targets have emerged from the stud-
ies of the genetic profiling of melanomas through the 
identification of genetic mutations involved in the 
pathogenesis and malignant transformation of the mel-
anocytes. Alterations of the RAS/RAF/MEK/ERK sig-
nalling cascade are considered drivers in majority of 
cutaneous melanomas development. NF1 is a tumor 
suppressor gene mutated in 10–15% of melanoma cases 
and is the third most frequently mutated gene in mela-
noma. KIT is an oncogenic driver associated with acral 
melanoma, and both are involved in proliferation and 
survival through the PI3K/AKT and the RAS/RAF/
MEK/ERK pathways. Indeed, selective RAF and MEK 
and the PI3K)/AKT kinase pathways inhibitors (vemu-
rafenib and dabrafenib) alone and/or in combination 
with MEK inhibitors (cobimetinib and trametinib) 
have shown promising results in clinical trials. For tar-
geted therapy thus, it is possible to select the patients 
who will benefit from these treatments, based on the 
mutational profile of the tumor. Only patients with 
tumours harbouring BRAF mutations should undergo 
treatment with a BRAF inhibitor, and patients with 
known RAS-mutant should not receive this treatment. 
Several studies have indicated that BRAFV600E detec-
tion through ctDNA prior to the commencement of 
treatment is predictive of the response to BRAF kinase 
inhibitors, and that high basal ctDNA levels are asso-
ciated with a lower response rate and progression-free 
survival. However, the clinical benefit of these therapies 
is limited, due to the rapid development of resistance 
through multiple mechanisms. Combination therapies 
seem to be an adequate strategy for melanoma patients, 
to overcome the resistance. Targeting signalling effec-
tors downstream of driver oncogenes is a valid strat-
egy to overcome resistance to BRAF inhibitors. MEK 
is a downstream target of BRAF and MEK inhibitors 
showed activity in NRAS-mutant melanomas.
Complex interactions between the tumor and the 
immune system play a role in melanoma development 
and metastatic spread to distant sites. Tissue infiltrating 
lymphocytes (TILs) recognize tumor-specific antigens, 
becoming activated and then proliferate and differenti-
ate, acquiring the capacity to destroy cells that express 
tumor-specific antigens. In addition, to the stimula-
tory and inhibitory signalling pathways that limit T-cell 
antitumoral responses, cancer cells can escape T-cell 
detection, as usually they do express PD-L1 molecule.
Immunotherapy appears to be a promising treatment 
option for patients with advanced stage malignant mela-
nomas, when compared to previous standard therapies, 
showing complete responses in selected patients. Major 
advances have been made in the treatment of metastatic 
melanoma using immune checkpoint blockade, with 
the FDA approval of numerous therapeutic regimens 
within the past several years and many more being stud-
ied in clinical trials. Treatment with immune checkpoint 
inhibitors such as monoclonal antibodies targeting cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) and 
programmed cell death protein 1 (PD-1) is associated 
with significant response rates, and many are durable. 
Several clinical trials are ongoing, using nivolumab and 
pembrolizumab in monotherapy or in combination with 
chemotherapy, radiotherapy, other immunotherapies, 
and targeted therapies are ongoing. Currently, the combi-
nation of two different immune checkpoint inhibitors or 
the combination of anti-PD1/anti-CTLA-4 with targeted 
therapy showed a clear benefit. However, most patients 
do not respond to these regimens as monotherapy, and 
some patients develop significant toxicity, particularly 
when these approaches are combined. There is a critical 
need to identify mechanisms of therapeutic resistance 
and adverse events in response to immune checkpoint 
inhibitors. There is emerging evidence that somatic 
mutations in antigen processing and presentation mech-
anism as well as up-regulation of genes involved in cell 
adhesion, angiogenesis, and extracellular matrix remod-
elling may contribute to immune escape in cancer. In 
addition, tumor-intrinsic oncogenic signals related to the 
WNT/β-catenin signalling pathway may mediate cancer 
immunity.
The immunogenic tumor microenvironment (TME), 
with mediators and cellular effectors of inflammation, 
influences the success of immunotherapies. The increas-
ing understanding of the biological determinants of 
melanoma evolution and their potential integration 
in the management of melanoma patients may lead to 
an improved diagnosis, patient risk determination and 
potential for stratification for treatment. In recent years, 
improved knowledge of the pathophysiology and the role 
of the immune system in tumor evolution have led to the 
development and approval of biomarker(s) correlating 
with response to immunotherapy.
Increased tumor PD-L1 expression assessed by PD-L1 
antibody using immunohistochemistry (IHC) and graded 
by the standardized scoring system is currently the only 
FDA approved and commercially available predictive 
biomarker in melanoma. At this point, PD-L1 expression 
on tumor specimens is not a candidate for pan-cancer 
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marker for PD-1 inhibitor treatment response, due to 
the heterogeneous results obtained from clinical trials. 
For example, responses were also seen in PD-L1 nega-
tive tumors, thus making use of PD-L1 expression con-
troversial and not standard of care in melanoma. While 
several genomic and immune predictors of response 
have been reported based on analysis of pre-treatment 
tumor biopsies, these biomarkers are not very robust, 
and there is significant overlap between responders 
and non-responders to therapy for the markers tested. 
Genomic studies exploring predictors of outcome to 
immune checkpoint blockade in melanoma suggest that 
tumor-specific mutational load and neoantigen signa-
ture are significantly associated with clinical benefit and 
increased overall survival. High mutational burden seems 
to associate with response in some studies, and it could 
correctly stratify the two groups of patients by response 
and predict progression free and overall survival. Gene 
expression profiling of the interferon-γ related profile 
was shown to predict best overall response, progression 
free survival, and overall survival in patients with mela-
noma treated with pembrolizumab. Immunohistochem-
istry-based studies also support the notion that CD8+ 
and CD4+ cell densities in pre-treatment biopsies can 
predict response to immunotherapy. Specific gut micro-
biota compositions can also drive differential responses 
to immune checkpoint inhibitors.
In addition to identifying predictors of response to 
immune checkpoint blockade, there is growing interest 
in understanding the mechanistic differences between 
different forms of immune checkpoint blockade. Tran-
scriptome and pathway analysis of T cells and monocytes 
from patients on either CTLA-4 or PD-1 blockade dem-
onstrates distinct gene expression profile and immuno-
logic effects between these forms of therapy. Whereas 
CTLA-4 blockade induces a proliferative signature in 
memory T cells, PD-1 blockade leads to changes in genes 
underlying cytotoxic functions and NK cell function. 
Studies in animal models also demonstrate differential 
effects of CTLA-4 and PD-1 blockade therapies on the 
transcriptional profiles of tumor-infiltrating CD8+ T 
cells.
Together, these data have shown potential in selecting 
patients who are more likely to respond to immunother-
apy and are currently being further investigated in clini-
cal trials using agents targeting PD1 pathway. However, 
cumulative evidence from these studies suggests that 
these biomarkers are not perfectly predictive, and bet-
ter biomarkers are clearly needed to optimize therapeu-
tic decisions. Integration of these molecular tests may 
provide more comprehensive insight into an individual 
tumor’s behaviour and ultimately guide difficult manage-
ment decisions in melanoma patients. Considering the 
complex biological interactions among different tumor 
pathways and their interplay with the immune system, 
bioinformatics approaches are required to yield conclu-
sive results that can be translate into clinically applicable 
assays.
These and other topics in the management of mela-
noma were the focus of discussions at the fourth Mela-
noma Bridge meeting (November 29th–December 1st, 
2018, Naples, Italy), which is summarised in this report.
Melanoma as a model system session
Neoadjuvant and adjuvant therapy for melanoma
Melanoma provides many opportunities to intervene 
therapeutically, including neoadjuvant and adjuvant 
therapy. In the adjuvant setting, interferon (IFN)-α is 
still available but is associated with high toxicity and its 
use remains controversial. It has, however, largely been 
superseded as checkpoint inhibitors and targeted agents 
have moved from the metastatic to adjuvant setting. In 
the first trial, 5-year relapse-free survival (RFS) rate with 
high-dose ipilimumab was 40.8% versus 30.3% with pla-
cebo (hazard ratio [HR] for recurrence or death, 0.76; 
P < 0.001) [1]. The overall survival (OS) rate at 5  years 
was 65.4% in the ipilimumab group compared with 
54.4% with placebo (HR for death, 0.72; P = 0.001). This 
is the only adjuvant trial of these new agents to date to 
have shown an OS benefit. Despite the improved treat-
ment, toxicity problems with ipilimumab, including five 
deaths in the trial, prevents it to be widely adopted and 
it appears unlikely to play a role as adjuvant treatment. 
The US Intergroup E1609 trial compared adjuvant ipili-
mumab (3 or 10  mg/kg) versus high-dose IFNα-2b for 
resected high-risk melanoma and found significantly less 
toxicity with the lower versus higher ipilimumab dose [2]. 
An unplanned RFS showed no difference in RFS between 
the two ipilimumab doses. Low-dose ipilimumab is 
undergoing further evaluation in the adjuvant setting.
Anti-PD-1 therapy has shown greater efficacy and 
less toxicity than ipilimumab in the adjuvant setting. In 
a trial of patients who underwent complete resection of 
stage IIIB-IV melanoma, nivolumab was associated with 
significantly improved 1-year RFS versus ipilimumab 
(70.5% versus 60.8%, HR for disease recurrence or death, 
0.65; P < 0.001) [3]. Improved RFS was also observed with 
adjuvant pembrolizumab, with a 1-year RFS rate of 75.4% 
versus 61.0% with placebo (HR for recurrence or death, 
0.57; P < 0.001) reported in patients with stage IIIA-C dis-
ease [4].
Adjuvant targeted therapy has also been shown to be 
effective. In patients with completely resected stage III 
BRAF-mutated melanoma, 3-year RFS rate was 58% with 
combined dabrafenib plus trametinib versus 39% with 
placebo (HR for relapse or death, 0.47; P < 0.001) with 
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early separation of curves [5]. Thus, three trials showing 
a consistent beneficial effect on RFS with adjuvant PD-1 
inhibitor therapy became available for melanoma patients 
although OS data is largely still awaited (Table 1).
Although there is no available head-to-head com-
parison data to demonstrate whether anti-PD-1 or tar-
geted therapy might be better option for BRAF-mutated 
patients, some differences can be noted. Anti-PD-1 ther-
apy is active irrespective of BRAF status and is effective 
in BRAF-mutant and wild-type patients. With immu-
notherapy, RFS curves appear to have a step in first 
1–3  months, after which the slope of the curve is flat-
ter than with targeted therapy. To date, there are only 
interim OS data for targeted therapy with no OS data 
for immunotherapy. RFS data are also more mature with 
targeted therapy. Discontinuation rate due to toxicity is 
higher with targeted therapy than immunotherapy (25% 
versus 6–8%); however, acute toxicity on targeted therapy 
can be resolved by stopping treatment whereas anti-PD-
1-related toxicity may be severe and require intervention. 
Trials conducted to date have subtle differences in the 
disease stages of enrolled patients which may be a con-
sideration in treatment choice. Ongoing studies are also 
investigating patients with high-risk stage II and stage IV 
disease. Adjuvant therapy should be considered standard 
of care in high-risk patients, although high-risk is not 
clearly defined. Patients with stage IIIa disease may have 
good survival without intervention.
A key question is whether more patients with stage 
III melanoma are being cured through adjuvant therapy. 
This is currently unclear but is being investigated in the 
KEYNOTE-054 trial, which will assess whether post-
surgery therapy with pembrolizumab improves RFS com-
pared to placebo for high-risk patients with melanoma. 
In part 1 of the trial, patients will receive pembrolizumab 
or placebo as post-surgery therapy for up to 1 year. Dur-
ing Part 2, patients in either arm with documented 
recurrence may receive optional re-treatment with pem-
brolizumab for up to 2 years or disease progression.
Neoadjuvant therapy provides the opportunity to 
treat early in the disease course when the immune sys-
tem should still be intact. It may reduce tumor burden 
before surgery and help guide additional adjuvant ther-
apy. Pathological complete response (pCR) may also 
be a surrogate for RFS and OS. This is an area of active 
research with many trials ongoing. In a phase II trial, 
neoadjuvant plus adjuvant dabrafenib and trametinib 
significantly improved event-free survival (EFS) ver-
sus standard of care (upfront surgery and consideration 
for adjuvant therapy) in patients with high-risk, clinical 
stage III-IV BRAF-mutated melanoma [6]. This trial was 
stopped early because of the very strong signal for better 
EFS in the neoadjuvant dabrafenib and trametinib arm. 
Trials are also investigating nivolumab plus ipilimumab 
in combination, with different dosing regimens being 
evaluated. In the OPACIN trial, neoadjuvant ipilimumab 
3 mg/kg plus nivolumab 1 mg/kg resulted in a 78% path-
ological response rate with all responders relapse-free 
after 3  years of follow-up [7]. However, 90% of patients 
experienced grade 3/4 toxicities. Nivolumab alone was 
less toxic but with an inadequate response rate. The 
subsequent OPACIN-NEO trial has reported a similar 
response rate with neoadjuvant ipilimumab 1 mg/kg plus 
nivolumab 3  mg/kg but with more manageable toxicity 
[8]. Pathological response was correlated with RFS and a 
baseline IFN-α signature was identified as a possible bio-
marker for treatment outcome.
Neoadjuvant therapy is a scientifically appealing 
approach with good data, but whether it will ever become 
standard of care is more questionable.
Table 1 Comparison of anti-PD-1 adjuvant trials
In italic values for 1-y RFS Rate (%), patients treated with nivolumab Grade 3-5 TREs (%) and patients treated with nivolumab DC Rate due to AEs (%)
Comparison of three trials showing a consistent beneficial effect on RFS with adjuvant PD-1 inhibitor therapy, although OS data is largely still awaited
Data comparison in adjuvant melanoma trials
Patient population CM238 [60] COMBI-AD [61] KN054 [4]
Completely resected stage IIIB/C 
or IV melanoma
Completely resected, BRAFV600E/K-
positive stage IIIA/B/C melanoma
Completely resected stage 
IIIA/B/C melanoma
Treatment Nivo Lpi Dab/Tram Placebo Pembro Placebo
N 453 453 438 432 514 505
RFS HR 0.65 (97.56% CI 0.51–0.83), P < 0.0001 0.47 (95% CI 0.39–0.58), P < 0.001 0.57 (98.4% CI 0.43–0.74), 
P < 0.001
1-year RFS rate (%) 71 61 88 56 75 61
18-months RFS rate (%) 66 53 N/A N/A 71 53
3-years OS rate (%) N/A N/A 86 77 N/A N/A
Grade 3–5 TRAEs (%) 14 46 31 5 15 3
DC rate due to AEs (%) 10 43 26 3 14 2
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Key points
• The use of interferon in the adjuvant setting has been 
superseded by checkpoint inhibitors and targeted 
agents that have moved from the metastatic to adju-
vant setting.
• Anti-PD-1 therapy has shown greater efficacy and 
less toxicity than ipilimumab in the adjuvant setting.
• Adjuvant targeted therapy has also been shown to be 
effective in patients with completely resected BRAF-
mutated melanoma, but toxicity is higher than with 
immunotherapy.
• Neoadjuvant therapy provides the opportunity to 
treat early in the disease course and is an area of 
active research interest with many trials ongoing.
Biomarkers in immunotherapy of melanoma: an update
Biomarkers for immunotherapy response in melanoma 
are not yet well established. However, two potential bio-
markers out of numerous candidate biomarkers that have 
been the subject of considerable investigation are tumor 
mutational burden (TMB) and circulating tumor DNA 
(ctDNA).
TMB is determined by whole exome sequencing (WES) 
after removal of germline DNA sequence variants to 
consider only somatic alterations. TMB is defined as 
the number of somatic, coding, base substitution, and 
indel mutations per megabase of genome examined. Tar-
geted next generation sequencing (NGS) panels, which 
are already being used for oncogenic mutation detec-
tion (e.g. by Foundation Medicine [F1CDx] and Memo-
rial Sloan Kettering Cancer Center [MSK-IMPACT] are 
now being validated against WES data. Both panels have 
been approved by the US Food and Drug Administration 
for targeted-DNA-sequencing panel for specific somatic 
mutations [9].
Numerous clinical trials since 2014 have included TMB 
as a potential biomarker. In a study of 35 patients with 
stage IV melanoma treated with combined nivolumab 
and ipilimumab, an NGS panel sequencing of 710 tumor-
related genes was used to assess TMB. High TMB was 
associated with significantly better OS, melanoma-spe-
cific survival and response, while patients with progres-
sive disease had lower TMB. Patients who had received 
targeted therapy prior to immunotherapy had less favour-
able outcomes. High TMB has also been shown to be an 
independent predictor of response to immunotherapy in 
a diverse array of other cancers, including non-small-cell 
lung cancer (NSCLC) [10].
Certain cancer types have higher rates of high TMB 
tumors, especially those affected by exogenous carcino-
gens including UV and tobacco, such as melanoma, other 
skin cancers and lung cancer. The underlying mechanism 
of the TMB being independent biomarker for immuno-
therapy, is increased number of neoantigens resulting 
from SNVs that provides a higher likelihood a tumor 
being recognized as foreign. For patients with low TMB, 
studies to assess whether targeted agents and combina-
tion treatments may be more effective than immunother-
apy are needed.
Analysis of ctDNA may also be a potential biomarker 
for response to immunotherapy. In a study of 76 meta-
static melanoma patients treated with anti-PD-1 agents, 
significantly higher responses were seen in patients with 
undetectable ctDNA at baseline or elevated ctDNA at 
baseline but undetectable within 12  weeks of therapy 
compared to patients with elevated ctDNA at baseline 
that remained elevated during treatment [11]. Better 
PFS and OS were reported in patients with undetectable 
ctDNA at baseline or after 12  weeks. In another trial, 
a significant reduction in ctDNA levels after 2  weeks 
of treatment relative to baseline was associated with a 
clinical response to anti-PD-1 therapy, while a persis-
tent decrease in ctDNA was associated with a durable 
response [12]. Patients with undetectable baseline ctDNA 
also had significantly improved OS, although this effect 
was not observed for PFS. It is not yet clear whether 
decrease in ctDNA levels during therapy or baseline level 
may be more important as a prognostic factor.
Key points
• Two potential biomarkers for immunotherapy that 
are of interest are tumor mutational burden (TMB) 
and circulating tumor DNA (ctDNA).
• Certain cancer types, such as melanoma, have higher 
rates of high TMB tumors and high TMB is an inde-
pendent predictor of response to immunotherapy.
• For patients with low TMB, studies to assess whether 
targeted agents may be more effective than immuno-
therapy are needed.
• Higher response to anti-PD-1 therapy has been 
reported in patients with undetectable ctDNA at 
baseline and in patients with significant reductions in 
ctDNA after starting treatment.
• It is not yet clear whether decrease in ctDNA lev-
els during therapy or baseline level can serve as an 
important as a prognostic factor.
Mechanisms of targeted therapy resistance: from BRAF 
to NRAS mutant melanoma
Distinct genetic subtypes of melanoma with mutations 
in BRAF or NRAS develop resistance to MAPK inhibi-
tors via hyper-activation of and addiction to the MAPK 
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pathway. The convergence of multiple resistance mecha-
nisms that reactivate (on drug) and hyper-activate (off 
drug) the MAPK pathway is a significant problem, which 
is only starting to be addressed by the combination of 
type I RAF inhibitors and allosteric MEK inhibitors. 
Because resistance is still commonly observed in BRAF 
mutant melanoma treated with BRAF and MEK inhibi-
tors, additional strategies are warranted.
It is noteworthy that MEK inhibitors display marginal 
activity against NRAS-mutant melanoma (NEMO trial), 
likely due to both immunologic and tumor cell-intrinsic 
resistance [13]. Importantly, activity of MEK inhibi-
tor in this trial was mostly limited to patients with prior 
treatment and failure on immune checkpoint blockade 
therapy. Also supported by preclinical studies in multi-
ple syngeneic tumor models, including those of BRAF, 
NRAS and NF1 murine melanoma, the activity of a MEK 
inhibitor combined with anti-PD-1 blockade in patients 
with BRAF wild-type melanoma that displays innate anti-
PD-1 resistance was studied. If anti-PD-1 therapy, despite 
innate resistance, primes a subsequent MEK inhibi-
tor response, this sequencing paradigm may be broadly 
applicable to MAPK pathway-addicted cancers.
MAPK inhibitor resistance in melanoma is quite robust 
in experimental NRAS mutant melanoma with acquired 
resistance to a MEK inhibitor. Augmentation of MAPK 
resistance to achieve regression of melanoma can be 
achieved by discontinuation of the MEK inhibitor fol-
lowed by addition of a PARP inhibitor [14]. This synthetic 
lethality strategy approach was already proposed in the 
clinic.
Finally, RAF dimerization among distinct resistance 
mechanisms (involving MAPK-reactivation) implies that 
next-generation MAPK inhibitors, such as dimeric RAF 
inhibitors, might be useful combinatorial partners to 
MEK inhibitors across all MAPK-dependent subtypes of 
melanoma. The combination of a dimeric RAF inhibitor 
with an allosteric MEK inhibitor can be highly synergis-
tic, with the former having little activity alone. How these 
two classes of MAPK inhibitor work synergistically given 
their promise to overcome MAPK inhibitor resistance in 
BRAF, NRAF melanoma is under investigations.
Key points
• The convergence of multiple resistance mechanisms 
that reactivate (on drug) and hyper-activate (off drug) 
the MAPK pathway is a significant problem in treat-
ment of melanoma.
• MEK inhibitors display marginal activity against 
NRAS mutant melanoma, likely due to both immu-
nologic and tumor cell-intrinsic resistance.
• Anti-PD-1 therapy, despite innate resistance, may 
prime a subsequent MEK inhibitor response, sug-
gesting that such sequencing paradigm may be 
broadly applicable to MAPK pathway-addicted can-
cers.
• Another strategy to overcome MAPK inhibitor 
resistance in melanoma involves exploitation of the 
MAPK inhibitor addiction phenotype. Discontinua-
tion of the MEK inhibitor followed by addition of a 
PARP inhibitor to achieve regression of melanoma 
could represent one of the approaches.
• Next-generation MAPK inhibitors, such as dimeric 
RAF inhibitors, might be useful combinatorial part-
ners to a MEK inhibitor across all MAPK-dependent 
subtypes of melanoma.
Clinical evidence emerging from radiation 
and immunotherapy
The pre-existing immune infiltrate in tumors drives prog-
nosis and response to immune checkpoint blockade. 
Integration of ionizing radiation targeted at lesions may 
help improve response to immunotherapy, as initially 
demonstrated in a syngeneic mouse model of breast can-
cer in which radiation and cytotoxic T-lymphocyte-asso-
ciated antigen (CTLA)-4 blockade resulted in improved 
survival due to T cell-mediated control both of the irra-
diated tumor and lung metastases, as evidence for an 
abscopal effect [15]. The optimal dose and fractionation 
of radiation in combination with immunotherapy for 
the abscopal effect is yet unknown. Single dose 30  Gy 
radiation with anti CTLA-4 has been shown to preclude 
the abscopal effect and this has been attributed to the 
induction of DNA exonuclease Trex1 by radiation doses 
above 12–18  Gy per fraction in different cancer cells. 
Trex1 attenuates immunogenicity by degrading DNA 
that accumulates in the cytosol upon radiation [16]. 
Cytosolic DNA stimulates secretion of IFN-β by cancer 
cells following activation of the DNA sensor cGAS and 
its downstream effector STING. Repeated irradiation at 
doses that do not induce Trex1 amplifies IFN-β produc-
tion, required for priming of CD8+ T cells that mediate 
the abscopal effect in the context of immune checkpoint 
blockade. These preclinical findings suggest that optimal 
effects of radiation and immune checkpoint blockade 
depend upon the dose per fraction of radiation used.
Consistently, the use of pembrolizumab in combina-
tion with classical large single doses of radiotherapy in 
patients with advanced solid tumors resulted in disap-
pointing results, with an overall objective response 
rate (ORR) of 13% and no complete responses [17]. 
Interestingly, in another study, patients with metastatic 
NSCLC who received pembrolizumab and radiotherapy 
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delivered in 3 fractions of 8 Gy had a significantly bet-
ter response versus patients receiving pembrolizumab 
alone (41% vs 19%) [18]. These contrasting results pro-
vide preliminary evidence for a dose/fraction effect, 
that confirm the preclinical data.
Another question is whether radiotherapy and check-
point blockade should be concurrent or sequential. In 
the PACIFIC trial, durvalumab after chemo radiother-
apy significantly increased progression-free survival 
(PFS) irrespective of PD-ligand (L) 1 expression at base-
line [19]. In another study in patients with advanced 
NSCLC, previous treatment with radiotherapy, even 
up to a year earlier, resulted in longer PFS and OS with 
pembrolizumab treatment than that in patients without 
previous radiotherapy [20].
Can radiation therapy in combination with immune 
checkpoint blockade convert an irradiated human 
cancer into an in  situ vaccine? CTLA-4 blockade had 
previously failed to demonstrate significant efficacy 
alone or with chemotherapy in locally advanced and 
metastatic NSCLC. However, in a trial of 39 patients 
with chemo-resistant metastatic NSCLC the addition 
of focal radiation therapy to one metastasis during 
ipilimumab induced systemic anti-tumor T cells and 
achieved an 18% ORR, indicating that radiation had 
‘repositioned’ CTLA-4 checkpoint inhibition in this 
disease setting [21]. There was no association between 
response and site of irradiation or previous PDL-1 
tumor expression. Increased serum IFN-β post-radia-
tion and early dynamic changes of blood T cell clones 
were the strongest predictors of response.
Radiotherapy plus immune checkpoint inhibition can 
generate neo-epitopes that impart a memory effect. 
Functional analysis in one responding patient showed 
the rapid in vivo expansion of CD8 T cells recognizing 
a neoantigen encoded in a gene that is upregulated by 
radiation and was mutated in that specific patient. This 
case supports the hypothesis that radiation-induced 
exposure of immunogenic mutations to the immune 
system explain the immunogenicity of radiation (that 
can clinically manifest as abscopal response). The gene 
that encoded this mutation in karyopherin A2 (KPNA2, 
also known as importin-α) is known to be upregulated 
by radiotherapy in human cancer cells in vitro and was 
also upregulated in  vivo after radiation in a patient-
derived xenograft NSCLC model.
Key points
• Ionizing radiation targeted at lesions may help 
improve response to subsequent immunotherapy.
• The optimal dose and fractionation of radiation in 
combination with immunotherapy for the abscopal 
effect is yet unknown.
• Preclinical evidence suggests that the optimal effects 
of radiation and immune checkpoint blockade 
depend upon the dose per fraction of radiation used.
• Radiotherapy plus immune checkpoint inhibition can 
generate neo-epitopes that impart a memory effect.
Mechanisms of resistance and drivers of response 
session
Targeted therapy and immunotherapy: rational 
for combination and future perspectives
Immunotherapy is slow-acting with the potential for 
long-term benefit while targeted therapy is fast-act-
ing and promotes a rapid metabolic shutdown but 
with possible resistance. In the BRIM-7 study of cobi-
metinib and vemurafenib in BRAF-mutant melanoma, 
OS appeared to plateau at 4  years with an OS rate of 
39% that was maintained at 5 years, suggestive of a sub-
group of patients with prolonged survival [22]. In a 
pooled analysis of trials, baseline lactate dehydrogenase 
(LDH), ECOG performance status, disease burden, and 
gene signature appeared to be key determinants of sur-
vival outcomes in patients treated with cobimetinib plus 
vemurafenib [23]. In the most favourable subgroup (nor-
mal LDH and baseline sum of longest diameters of tar-
get lesions [SLD] ≤ 45  mm), 3-year OS rate was 53.3% 
with cobimetinib plus vemurafenib. The immune signa-
ture was enriched in favourable clinical prognostic sub-
groups, consistent with an immunosuppressive effect of 
oncogenic BRAF signalling on the tumor-host interaction 
and beneficial effects of MEK inhibition on response to 
immune checkpoint inhibitors. Baseline LDH and SLD 
were also predictive of PFS and OS in a 3-year pooled 
analysis of trials of dabrafenib and trametinib combina-
tion therapy [24].
The first evidence that lack of PD-L1 expression and 
presence of immune cell infiltration predict a better 
response in BRAF inhibitor-treated BRAFV600-mutant 
melanoma was reported by Massi et  al. in 2015 [25]. 
However, patients with < 1% CD8+ T cells in the tumor 
centre or lower PD-L1 expression have been observed to 
derive clear benefit from vemurafenib. These data suggest 
an immune-action of tyrosine kinase inhibitors.
Three immune phenotypes point to disruption of spe-
cific steps of the cancer-immunity cycle. The immune 
desert phenotype involves non-inflamed tumors with lit-
tle or no CD8+ T-cell infiltration, the immune-excluded 
phenotype involves non-inflamed tumors but with the 
presence of CD8+ T-cells residing solely in the periph-
ery, and the immune-inflamed phenotype involves the 
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presence of intratumoral CD8+ T-cell infiltrate. Each 
phenotype requires a different strategy to reinitiate 
the anti-tumor immune response. For immune desert 
tumors, the aim is to generate, release and deliver anti-
gens, and enhance antigen presentation and T-cell prim-
ing. For immune-excluded tumors, the goal is to recruit T 
cells to the tumor and address the stromal barrier, while 
for already inflamed tumors, the goal is to invigorate T 
cells. Redirecting and engaging T cells is required for all 
tumor phenotypes. Blocking the MAPK signalling path-
way results in changes in the TME, including increased 
melanoma antigen expression, decreased immunosup-
pressive cytokine production, increased CD8+ T-cell 
infiltration, increased T-cell clonality, increased PD-L1 
expression and class I MHC upregulation. This may mean 
tumor cells are more visible and hence more susceptible 
to immunotherapy.
MEK inhibition may help to unleash a greater anti-
tumor potential of PD-L1 inhibition via direct effects on 
T cells and the TME. For example, increases in CD8+ 
T cells have been observed following cobimetinib plus 
vemurafenib. Several trials combining BRAF and MEK 
inhibition with an anti-PD-1/PD-L1 agent are ongoing 
with promising results. These include combined ate-
zolizumab plus vemurafenib and cobimetinib in BRAF 
V600-mutant metastatic melanoma, which has shown 
promising antitumor activity and a manageable safety 
profile in phase I data with phase II/III studies ongoing 
[26]. Another emerging combination approach to modu-
late tumor immunogenicity is based on the use of histone 
deacetylase (HDAC) inhibitors, epigenetic modifiers that 
exert this effect on cancer cells as well as on immune cells 
and components of the TME [27]. Several clinical trials 
of HDAC inhibitors in combination with immune check-
point blockers are ongoing. For example, the efficacy and 
safety of the HDAC inhibitor entinostat and pembroli-
zumab in patients with melanoma progressing on or after 
PD-1/L1 blocking antibody, has recently been reported 
[28].
Key points
• Immunotherapy is slow-acting with the potential 
for long-term benefit while targeted therapy is fast-
acting and promotes a rapid metabolic shutdown but 
with possible resistance.
• The immune signature is enriched in prognostic sub-
groups with a favourable response to BRAF and MEK 
inhibition, consistent with an immunosuppressive 
effect of oncogenic BRAF signalling on the tumor-
host interaction.
• Blocking the MAPK signalling pathway results in 
changes in the TME that may mean tumor cells are 
more visible and hence more susceptible to immuno-
therapy.
• Several trials combining with an anti-PD-1/PD-L1 
agent are ongoing with promising results.
Exosomes in melanoma
Tumors produce and release a variety of extracellular 
vesicles, the smallest (30–150  nm) of which are called 
exosomes. These tumor-derived exosomes (TEX) have 
recently emerged as carriers of numerous receptors, 
ligands and factors that modulate functions of recipient 
cells. Because of their endocytic origin and the protein/
genetic cargo, which mimics that of parent tumor cells, 
TEX have emerged as potential circulating biomarkers 
for parent tumor cells. TEX also serve as regulatory ele-
ments, because they reprogram and alter the functions of 
recipient cells, carry numerous immunoinhibitory signals 
and down-regulate functions of effector immune cells. 
TEX also re-program immune cells and could serve as 
potential immune biomarkers.
To date, TEX have largely been studied as by-prod-
ucts of tumor cell lines maintained in cultures. Studies 
of plasma-derived exosomes have been challenging, and 
several limitations have been identified, including the 
lack of a rapid and cost-effective isolation method for 
exosomes in body fluids. However, isolation of intact, 
biologically active exosomes from cancer patients’ plasma 
or other body fluids is now possible by mini-size exclu-
sion chromatography (mini-SEC) [29].
The monoclonal antibody 763.74 is specific for a pep-
tide epitope of a tumor antigen expressed on melanoma 
cells and not generally detectable on normal cells, chon-
droitin sulphate peptidoglycan 4 (CSPG4) can be used to 
capture melanoma cell-derived exosomes. The CSPG4 
epitope is present on > 80% of melanomas and is carried 
by exosomes produced by melanoma cells. CSPGs are 
key bioactive molecules that play a major role in tumor 
growth, migration and neo-angiogenesis.
Melanoma-derived exosomes (MTEX) were sepa-
rated from non-tumor cell-derived exosomes and 
the protein cargo of both fractions were evaluated by 
quantitative flow cytometry [30]. Melanoma-associ-
ated antigens (CSPG4, TYRP2, Melan A, Gp100 and 
VLA4 were carried by MTEX, especially those from 
patients with advanced disease, but were not detect-
able in exosomes produced by normal cells. MTEX 
were enriched in FasL and TRAIL whereas non-MTEX 
were enriched in co-stimulatory proteins (CD40, 
OX40, OX40L). MTEX co-incubated with human pri-
mary T cells inhibit T-cell proliferation and MTEX co-
incubated with primary activated CD8+ T cells induce 
apoptosis. Thus, isolated exosomes maintain their 
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morphology and are functional. The ability to isolate 
functional MTEX and to assess for melanoma-associ-
ated antigens or other molecular or genetic markers of 
the tumor will facilitate testing of the role of MTEX as 
liquid biopsies in melanoma.
Key points
• Tumors produce and release a variety of extracellular 
vesicles, the smallest of which are exosomes, carriers 
of numerous receptors, ligands and factors that mod-
ulate functions of recipient cells.
• These tumor-derived exosomes (TEX) emerged as 
potential circulating biomarkers for parent tumor 
cells.
• Isolation of intact, biologically active exosomes from 
cancer patients’ plasma or other body fluids is now 
possible by mini-size exclusion chromatography.
• Melanoma-derived exosomes (MTEX) carry mela-
noma-associated antigens that are not detectable in 
exosomes produced by normal cells.
• The ability to isolate functional MTEX and to assess 
for melanoma-associated antigens or other molecular 
or genetic markers of the tumor will facilitate testing 
of the role of MTEX as liquid biopsies in melanoma.
Intestinal ecosystem and immunity against melanoma
The relationship between the gut microbiome and host 
immunity raises the possibility that dysbiosis of the intes-
tinal flora may influence the outcome of cancer immuno-
therapy. It has been shown that the anti-tumor efficacy 
of CTLA-4 blockade is supported by gut bacteria, with T 
cell responses specific for Bacteroides thetaiotaomicron 
or B. fragilis associated with improved efficacy [31]. It 
has also been shown that antibiotics inhibited the clinical 
benefit of anti-PD-1 or anti-PD-L1 treatment in patients 
with advanced cancer, significantly reducing PFS and 
OS [32]. Antibiotics were also associated with reduced 
clinical benefit from immune checkpoint inhibitors in 
patients with advanced renal cell carcinoma (RCC) or 
NSCLC [33].
Various methods can be utilized to help better under-
stand the clinical relevance of the composition of the gut 
microbiome (Fig. 1).
The transplantation of fecal microbiota (FMT) from 
cancer patients who responded to immune checkpoint 
blockade into germ-free or antibiotic-treated avatar mice 
ameliorated the anti-tumor effects of PD-1 blockade, 
unlike FMT from non-responding patients [32].
Shotgun, or untargeted, metagenomic sequenc-
ing, which uses genetic analyses of DNA from several 
types of cells, performed in two independent cohorts of 
patients with advanced RCC or NSCLC revealed that 
How to decipher the clinical relevance of 
the composition of the gut microbiome? 
Culturomics of 
paents stools (N vs NR)
Circulang memory T cell responses
against commensals
Avatar plaorm MetagenomicsShot gun DNA Seq
Fig. 1 How to decipher the clinical relevance of the compositions of the gut microbiome? Various methods can be utilized to help better 
understand the clinical relevance of the composition of the gut microbiome
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Akkermansia muciniphila, Alistipes spp. and Ruminococ-
caceae spp. were enriched in responders to checkpoint 
blockade.
Akkermansia muciniphila was validated as a predictor 
of best outcome in a second cohort of patients treated 
with anti-PD-1 antibodies. Circulating memory T cell 
responses against commensal bacteria were also investi-
gated and showed that T cell responses against A. mucin-
iphila and Enterococcus hirae were associated with longer 
survival during PD-1 blockade. Enhanced systemic and 
anti-tumor immunity was suggested in patients who 
responded to checkpoint inhibitors with a favourable 
gut microbiome and in germ-free mice receiving fecal 
transplants from responders. The classical method of 
stool culturomics also revealed that E. hirae were more 
frequent in faeces from patients with NSCLC who 
responded to anti-PD-1 treatment compared to non-
responders. Restoration of anti-PD-1 antibody efficacy 
has been demonstrated using A. muciniphila across dif-
ferent tumor models using FMT from different patients. 
Random bacteria (E. faecalis or B. nordii) did not com-
pensate the dysbiosis.
Studies to assess the role of the microbiome in mela-
noma are now ongoing. One trial is investigating con-
current FMT with pembrolizumab in patients with 
PD-1 resistant/refractory melanoma. Another study will 
involve altering the gut microbiota of melanoma patients 
scheduled to receive PD-1 blockade using FMT from 
patients who responded to anti-PD-1 therapy. In the 
future, microbiome modulation may become an impor-
tant modality in cancer therapy.
Key points
• Dysbiosis of the intestinal flora may influence the 
outcome of cancer immunotherapy and it has been 
shown that the anti-tumor efficacy of CTLA-4 
blockade is supported by gut bacteria, with T cell 
responses specific for Bacteroides spp. associated 
with improved efficacy.
• Antibiotics may inhibit the clinical benefit of anti-
PD-1 or anti-PD-L1 treatment in patients with 
advanced cancer.
• Enhanced systemic and anti-tumor immunity was 
suggested in patients who responded to checkpoint 
inhibitors with a favourable gut microbiome and 
in germ-free mice receiving fecal transplants from 
responders.
• Studies to assess the role of the microbiome in mela-
noma are now ongoing with the hope that microbi-
ome modulation may become an important modality 
in cancer therapy.
Tumor and host factors regulating immunotherapy efficacy
The T cell-inflamed and non-inflamed TMEs represent 
two categories of immune escape. Whereas the T cell-
inflamed tumor is characterized by chemokine expres-
sion increased CD8+ T cells and a type I IFN signature 
with immune escape via inhibitory pathways resulting 
in increased anti-PD-1 efficacy, non-inflamed tumors 
have a low inflammatory signature and absent intra-
tumoral CD8+ T cells with immune escape via T cell 
exclusion, meaning anti-PD-1 efficacy is diminished. 
Activity of anti-PD-1 in multiple cancers is associated 
with a T cell-inflamed TME signature at baseline and 
the T cell-inflamed TME serves as an approximate 
predictive biomarker for response to anti-PD-1-based 
immunotherapies [34].
Although the presence of tumor-infiltrating lym-
phocytes (TILs) indicates an endogenous antitumor 
response, multiple immune regulatory pathways can 
subvert the effector phase and enable tumor escape. 
Negative regulatory pathways include extrinsic sup-
pression mechanisms, but also a T cell-intrinsic dys-
functional state characterized by co-expression of 
the cell surface proteins lymphocyte-activating gene 
(LAG)-3 and 4-1BB. LAG-3 and 4-1BB+ TILs actively 
proliferate in  situ but also actively apoptose, creating 
a self-defeating cycle. TIL apoptosis is associated with 
antigen-induced T-cell dysfunction, possibly due to the 
accumulation of DNA damage in dysfunctional TILs. 
A 4-1BB agonist antibody synergised with checkpoint 
blockade to decrease TIL apoptosis and enhance tumor 
control [35]. Mechanisms of human TIL apoptosis 
should be investigated to develop new potential thera-
peutic strategies for T cell-inflamed tumors.
Molecular mechanisms to explain the T cell-inflamed 
versus non-inflamed TMEs include somatic differ-
ences at the level of tumor cells e.g. the mutational 
landscape and antigenic repertoire and distinct onco-
gene pathways activated in different patients, germline 
genetic differences at the level of the host such as poly-
morphisms in immune regulatory genes, and environ-
mental differences in commensal microbiota and the 
immunological exposure history of patients.
Multiple lines of evidence indicate a critical role for 
Batf3-lineage dendritic cells (DCs) at multiple levels 
in anti-tumor immunity and immunotherapy efficacy. 
The first oncogene pathway identified that mediates 
immune exclusion is the Wnt/β-catenin pathway. 
Tumor cell-intrinsic β-catenin activation prevents the 
host anti-tumor immune response by failure to recruit 
Batf3 DCs, upon which the recruitment of effector 
CD8+ T cells is dependent [36]. Batf3-lineage DCs are 
involved in both the priming phase and the effector 
phase of the anti-tumor immune response and there is 
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a loss of efficacy of anti-PD-L1 upon depletion of DCs 
at the effector phase.
T cell exclusion from the TME mediated by β-catenin, 
PTEN loss, and other oncogenic events is prompting 
re-focused drug development. Activation of tumor-
intrinsic WNT/β-catenin signalling is enriched in 
non-T cell-inflamed tumors and secondary recurrence 
in melanoma is associated with upregulated β-catenin 
and loss of immune signature. Secondary resistance to 
ipilimumab and nivolumab has also been associated with 
PTEN deletion.
Molecular mechanisms that mediate the presence or 
absence of the T cell-inflamed TME are being elucidated 
using parallel genomics platforms. In vitro screening for 
genetic alterations is identifying genes (MHC class I, 
IFN-γR2, Jak1) mediating resistance to T cell-mediated 
killing. Multidimensional ‘omics’ analyses are identifying 
individualized molecular correlates of response versus 
resistance in patients, including commensal microbiota 
and germline genetic variants.
Key points
• The T cell-inflamed and non-inflamed TME repre-
sents two categories of immune escape.
• Activity of anti-PD-1 is associated with a T cell-
inflamed TME signature at baseline and the T cell-
inflamed TME serves as an approximate predictive 
biomarker for response to anti-PD-1-based immuno-
therapies.
• Mechanisms of human TIL apoptosis should be 
investigated to develop new potential therapeutic 
strategies for T cell-inflamed tumors.
• Molecular mechanisms that mediate the presence or 
absence of the T cell-inflamed TME are being eluci-
dated using parallel genomics platforms.
Intratumoral immunotherapy a weapon beyond a “mass” 
destruction
There are many ongoing studies evaluating oncolytic 
intratumoral immunotherapy in combination with check-
point inhibition. The already approved oncolytic virus 
talimogene laherparepvec (T-VEC) had a tolerable safety 
profile in combination with ipilimumab with improved 
efficacy versus either T-VEC or ipilimumab monotherapy 
in a phase Ib trial in patients with advanced melanoma 
[37]. In a phase II study, ORR was significantly higher 
with T-VEC plus ipilimumab versus ipilimumab alone 
(39% versus 18%) without additional safety concerns [38]. 
T-VEC is also now being assessed in combination with 
pembrolizumab in the phase III MASTERKEY-265 trial.
HF10 is a bioselected replication-competent onco-
lytic virus also derived from HSV-1 that demonstrated 
a favourable benefit/risk profile and encouraging anti-
tumor activity with a best ORR of 41% when combined 
with ipilimumab in patients with stage IIIB–IV unre-
sectable or metastatic melanoma [39]. A second onco-
lytic virus demonstrating promising clinical findings is 
coxsackievirus A21 (CVA21). An immunotherapeutic 
strain of CVA21 was assessed in combination with ipili-
mumab and showed clinical activity with a best ORR of 
38% together with low adverse toxicity in patients pre-
viously treated with anti-PD-1 agents [40].
An intralesional agent, PV-10, which contains an 
injectable formulation of rose bengal disodium, is being 
assessed in combination with pembrolizumab. Interim 
results from a phase Ib trial indicated robust responses 
in target lesions, a 65% ORR with no unexpected toxici-
ties [41].
Interleukin (IL)-12 augments the immune response 
but systemic IL-12 can cause significant toxicity. This 
can be avoided through electroporation which facili-
tates cell entry of plasmid IL-12 and results in high 
levels of IL-12 protein expression. Intratumoral plas-
mid IL-12 with electroporation increases TILs in both 
treated and untreated lesions. In patients treated with 
IL-12 electroporation and pembrolizumab, a 40% clini-
cal response rate was observed and good tolerability 
[42].
The rationale for combining intralesional therapy with 
checkpoint blockade is the potential synergy from the 
immune stimulation effected after intralesional agents 
promote the release and presentation of tumor-derived 
antigens, thereby increasing TILs and turning tumors 
from an immunologically ‘cold’ to ‘hot’ status. A signifi-
cant proportion of patients do not respond to immune 
checkpoint blockade. Identifying patients unlikely to 
respond is a challenge but the relative abundance of par-
tially exhausted tumor-infiltrating CD8+ T cells has been 
shown to predict response to anti-PD-1 therapy [43]. 
Intralesional agents offer the potential to increase CD8+ 
T cells in the tumor, making them more responsive to 
immune checkpoint inhibition.
Key points
• Ongoing studies are evaluating oncolytic intratu-
moral immunotherapy in combination with check-
point inhibition.
• Oncolytic virus demonstrating promising clinical 
findings include HF10, a bioselected replication-
competent oncolytic virus derived from HSV-1, and 
coxsackievirus A21 (CVA21).
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• An intralesional agent, PV-10, which contains an 
injectable formulation of rose bengal disodium, is 
being assessed in combination with pembrolizumab.
• Intratumoral plasmid IL-12 with electroporation has 
shown promising activity in patients and good toler-
ability.
• Intralesional therapy may promote the release and 
presentation of tumor-derived antigens, thereby 
turning tumors from an immunologically ‘cold’ to 
‘hot’ status and so providing potential synergy with 
checkpoint blockade.
Emerging strategies session
Translational research in the therapeutic landscape 
for metastatic melanoma
One of the major technologies in translational research 
is NGS, with many studies having used WES or whole 
genome sequencing (WGS) on melanoma tumors, mela-
noma short term cultures or melanoma cell lines. How-
ever, a multitude of other cutting-edge technologies are 
also involved in translational research. These include 
single-cell mass cytometry/imaging mass cytometry for 
in-depth characterization of tumor and immune com-
partments at single cell level, with identification of cell 
subsets including phenotypic and functional features. 
Fast drug-testing measures ex vivo drug responses using 
automated microscopy, single cell image-analysis, and 
machine learning, while deep drug testing for molecular 
characterization of tumor cell response to drug treat-
ment by analysing survival, proliferation, and differen-
tiation pathways. Genomics and transcriptomics can 
infer tumor heterogeneity by single-cell and bulk RNA 
sequencing and single cell DNA sequencing to identify 
and quantify tumor sub-clones and normal cell types in 
the TME, including immune cell subtypes.
Some examples of the role of these techniques in 
translational research in melanoma are outlined below. 
Single-cell RNA sequencing of malignant cells isolated 
from BRAF-mutant patient-derived xenograft melanoma 
cohorts exposed to concurrent RAF/MEK inhibition 
resulted in the identification of distinct drug-tolerant 
transcriptional states, varying combinations of which co-
occurred within minimal residual disease from patient-
derived xenografts and biopsies of patients on treatment 
[44]. One of these exhibited a neural crest stem cell 
(NCSC) transcriptional program largely driven by the 
nuclear receptor RXRG. An RXR antagonist mitigated 
accumulation of NCSCs in minimal residual disease and 
delayed the development of resistance.
Analysis of somatic mutanomes and transcrip-
tomes of pre-treatment melanoma biopsies identified 
a transcriptional signature (known as innate anti-PD-1 
resistance, IPRES), indicating concurrent up-expression 
of genes involved in the regulation of mesenchymal 
transition, cell adhesion, extracellular matrix remod-
elling, angiogenesis, and wound healing [45]. MAPK 
inhibitor therapy induces similar signatures in mela-
noma, suggesting that a non-genomic form of MAPK 
inhibitor resistance mediates cross-resistance to anti-
PD-1 therapy.
Single-cell RNA sequencing from melanoma tumors 
and computational analyses identified a resistance pro-
gram expressed by malignant cells that is associated 
with T cell exclusion and immune evasion. This pro-
gram is expressed prior to immunotherapy, character-
izes cold niches in situ, and predicted clinical response 
to anti-PD-1 therapy in an independent cohort of mela-
noma patients. CDK4/6-inhibition represses this pro-
gram in individual malignant cells, suggesting a new 
therapeutic strategy [46].
High-dimensional single-cell mass cytometry and 
a bioinformatics pipeline was used for the characteri-
zation of immune cell subsets in the peripheral blood 
of patients with advanced melanoma before and after 
12  weeks of anti-PD-1 therapy [47]. During therapy, a 
clear response to immunotherapy was seen in the T cell 
compartment. However, before commencing therapy, a 
strong predictor of PFS and OS was the frequency of 
CD14+CD16−HLA-DRhi monocytes. Thus, the fre-
quency of monocytes in peripheral blood mononuclear 
cells may support clinical decision-making.
Evaluation of > 300 patient samples across 22 tumor 
types from four KEYNOTE clinical trials of pembroli-
zumab identified both TMB and a T cell-inflamed 
gene expression profile as having predictive utility in 
identifying responders and non-responders to anti-
PD-1 therapy [48]. TMB and gene expression profile 
were independently predictive of response and dem-
onstrated low correlation, suggesting that they cap-
ture distinct features of neo-antigenicity and T cell 
activation. Immune gene expression signatures were 
also prognostic for response to combined BRAF/MEK 
inhibition [49]. High TMB added positive prognostic 
value to immune gene signatures in the placebo arm 
(high IFN-γ and high TMB associated with longer RFS), 
whereas IFN-γ gene signature identified patients with 
longer RFS independently of TMB status in the dab-
rafenib plus trametinib arm.
These examples all indicate a fundamental role of 
translational research in helping guide therapy. A clini-
cal goal of translational research is a multi-system pre-
dictive model to guide treatment decision-making in 
metastatic melanoma (Fig. 2).
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Key points
• In addition to NGS, a multitude of other cutting-
edge technologies are also involved in translational 
research, including single-cell mass cytometry/imag-
ing mass cytometry, fast drug-testing, deep drug, 
genomics and transcriptomics.
• Many examples of translational research indicate its 
fundamental role in helping guide therapy.
• A clinical goal of translational research is a multi-
system predictive model to guide treatment decision-
making in metastatic melanoma.
Role of adrenergic stress reversal in melanoma therapy
Adrenergic signalling promotes tumor growth and 
metastasis in many ways. Tumors are innervated by post-
ganglionic nerves of the sympathetic nervous system 
and, in response to stress, these nerves secrete norepi-
nephrine (NE). Many cells in the TME express adrenergic 
receptors, and their responses support tumor growth.
β-Adrenergic receptor signalling can influence immune 
cell function. NE signalling through β-adrenergic recep-
tors on T cells is highly suppressive, having been shown 
to decrease antigen-specific CD8+ T cell frequency 
and functionality, impair CD8+ T cell killing, suppress 
CD8+ T cell production of IFN-γ and tumor necrosis 
factor (TNF)-α, decrease IL-2 production and prolifera-
tion of TH1 CD4+ T cells, and prevent T cell egress from 
lymph nodes. However, most of this work has been done 
in models of infection and autoimmunity, and its role in 
cancer has been largely unexplored.
The effects of physical/physiological environmental 
stressors on tumor growth have not been as well studied 
but environmental factors can induce a stress response 
and alter internal metabolism and physiology. Mice 
housed at an ambient temperature of 30 °C have signifi-
cantly inhibited tumor growth compared to mice housed 
at standard temperatures (22 °C) even though mice under 
both conditions maintain a normal core body tempera-
ture of 37 °C [50]. Cold-stressed mice have elevated sys-
temic levels of NE. Chronic adrenergic signalling in 
cold-stressed mice promotes tumor growth by induction 
of antiapoptotic signalling molecules and by profound 
immunosuppression of the antitumor immune response. 
Reducing thermal stress helps to control tumor growth 
with this effect dependent on the adaptive immune 
system.
Reducing adrenergic stress by physiologic reduction of 
NE signalling improved anti-PD-1 efficacy [51]. Moreo-
ver, combining β-blockade with anti-PD-1 therapy had a 
synergistic inhibitory effect on tumor growth while anti-
PD-1 alone had no impact. The benefit of propranolol 
was lost in the absence of CD8+ T cells and proprano-
lol improved the functional orientation of CD8+ TILs as 
evidenced by increased expression of markers of effector 
function.
The question is whether the sympathetic nerv-
ous system can function as a checkpoint and regulate 
Fig. 2 A clinical endpoint of translational research. A clinical goal of translational research is a multi-system predictive model to guide treatment 
decision-making in metastatic melanoma
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anti-tumor immunity and response to cancer therapies? 
Retrospective observational data have suggested a sig-
nificant survival benefit for melanoma patients pre-
scribed pan β-blockers compared to either those taking 
no β-blocker or β1-selective blockers [52]. βAR block-
ade also enhanced control of murine melanoma growth 
by anti-PD-1 checkpoint blockade, with this effect most 
significant when a β-blocker was combined with dual 
anti-PD-1 and high-dose IL-2 therapy. Several other ret-
rospective studies have also suggested that the incidental 
use of β-blockers is beneficial to cancer patients.
Based on these findings, a phase IB/II study of pro-
pranolol with fixed-dose pembrolizumab in patients with 
unresectable stage III and stage IV melanoma has been 
initiated.
Key points
• Adrenergic signalling promotes tumor growth and 
metastasis.
• Norepinephrine (NE) signalling through β-adrenergic 
receptors on T cells is highly immunosuppressive, 
but its role in cancer has been largely unexplored.
• In preclinical studies, reducing adrenergic stress 
by physiologic reduction of NE signalling improved 
anti-PD-1 efficacy, while combining β-blockade with 
anti-PD-1 therapy had a synergistic inhibitory effect 
on tumor growth while anti-PD-1 alone had no 
impact.
• Several retrospective studies have suggested that the 
incidental use of β-blockers is beneficial to cancer 
patients.
• Based on these findings, a phase IB/II study of pro-
pranolol with fixed-dose pembrolizumab in patients 
with unresectable stage III and stage IV melanoma 
has been initiated.
Advancing the understanding and treatment of melanoma 
CNS metastases
Melanoma has the highest risk of brain metastases 
among solid tumors, occurring in 10–20% of patients at 
diagnosis of stage IV, up to 50% over the course of the 
disease and up to 70% at autopsy. Historically, median 
OS of patients with melanoma brain metastases has 
been approximately 4  months, with traditional blood–
brain barrier-penetrating chemotherapies achieving 
intracranial responses in less than 10% of patients. Tar-
geted agents and immunotherapies have demonstrated 
significant benefits in patients with metastatic disease 
but patients with active brain metastases have typically 
been excluded from large trials. Three recent studies in 
patients with melanoma brain metastases have provided 
promising results.
In the COMBI-MB trial, dabrafenib plus trametinib 
was assessed in patients with asymptomatic mela-
noma brain metastases [53]. After a median follow-up 
of 8.5 months, intracranial response rate was 58% in 76 
patients with BRAFV600E-mutant disease and with-
out prior local therapy. Similar response rates were also 
observed in smaller cohorts which varied by BRAF muta-
tion, prior local therapy and whether disease was symp-
tomatic or not. Median PFS was 5.6  months. Disease 
progression was intracranial only in 47% of patients. 
With regard to immune checkpoint inhibition, the effi-
cacy and safety of nivolumab plus ipilimumab has been 
evaluated in the CheckMate 204 study, in which the rate 
of intracranial clinical benefit was 57% in 94 patients with 
melanoma metastatic to the brain [54]. Intracranial PFS 
rate was 59.5%, with extracranial PFS rate only slightly 
higher and OS rate was 81.5% at 12 months. Nivolumab 
plus ipilimumab (versus nivolumab alone) were also 
assessed in patients with melanoma brain metastases in 
the Anti-PD1 Brain Collaboration (ABC) study [55]. At 
a median follow up of 17 months, intracranial responses 
were achieved by 46% patients receiving nivolumab plus 
ipilimumab and 20% receiving nivolumab monotherapy. 
Six-month intracranial PFS rate was 53% with the combi-
nation and 20% with nivolumab.
Systemic therapy for melanoma brain metastases has 
offered marked progress but more research is needed. 
Combination therapy with ipilimumab plus nivolumab 
is better than single-agent PD-1 therapy and represents 
a new standard of care for patients with asymptomatic 
brain metastases not requiring steroids but 30–40% of 
patients have progressive disease, toxicity is an issue and 
there are no data for patients on steroids. Targeted ther-
apy of combined BRAF and MEK inhibition offers rapid 
responses and initial disease control, including in patients 
on steroids. However, most responses are ≤ 6 months and 
around half of patients have intracranial before extracra-
nial progression. Next steps involve further investigation 
of different combinatorial approaches (e.g. stereotactic 
radiosurgery with immune checkpoint inhibitors), fur-
ther characterization of melanoma brain metastases to 
direct rational approaches, and more research into the 
treatment of symptomatic disease, patients with lep-
tomeningeal disease, and treatment options after fail-
ure on ipilimumab plus nivolumab or dabrafenib plus 
trametinib.
Key points
• Targeted agents and immunotherapies have demon-
strated significant benefits in patients with metastatic 
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disease but patients with active brain metastases 
have typically been excluded from large trials.
• Three recent studies in patients with melanoma 
brain metastases have provided promising results 
(COMBI-MB, CheckMate 204 and the Anti-PD1 
Brain Collaboration studies).
• Combination therapy with ipilimumab plus 
nivolumab is better than single-agent PD-1 therapy 
and represents a new standard of care for patients 
with asymptomatic brain metastases not requiring 
steroids.
• Targeted therapy of combined BRAF and MEK 
inhibition offers rapid responses and initial disease 
control, including in patients on steroids but most 
responses are ≤ 6 months and around half of patients 
have intracranial before extracranial progression.
• Next steps include further investigation of different 
combinatorial approaches, treatment options after 
failure on ipilimumab plus nivolumab or dabrafenib 
plus trametinib.
STING agonism and type I interferon to augment 
immunotherapy
A T cell-inflamed TME may serve as a predictive bio-
marker for response to immunotherapies. Given this, 
how can we approach non-T cell-infiltrated tumors? 
Innate immune sensing of tumors is largely driven by 
the STING pathway.  STING−/− mice fail to generate an 
effective spontaneous antitumor T-cell response, which 
is associated with defective recruitment and activation 
of the Batf3-lineage DCs expressing CD8α or CD103 
[56]. Downstream from STING pathway activation is 
the induction of type I IFNs which is critical for cross-
presentation of antigens by Batf3-lineage DCs to CD8+ 
T cells.
STING agonists may provide a means to deliber-
ately initiate innate immune inflammation to promote 
an endogenous T cell response in non-T cell-inflamed 
tumors. Intratumoral administration of the STING ago-
nist, MK-1454, results in complete tumor regression and 
enhances the efficacy of anti-PD-1 therapy in mouse syn-
geneic models. In a phase 1 study, MK-1454 in combina-
tion with pembrolizumab had encouraging efficacy and 
an acceptable safety profile in patients with advanced 
solid tumors or lymphoma [57]. Elevations in serum 
cytokines IL-6 and IP-10 and STING induced gene 
expression in blood were observed. Another intratumoral 
STING agonist, MIW815, was well tolerated as a single-
agent with no dose-limiting toxicities noted and signs of 
biological activity in patients with advanced solid tumors 
and lymphoma [58].
Stereotactic body radiotherapy (SBRT) may stimulate 
innate and adaptive immunity to augment response to 
immunotherapy. Multi-organ SBRT followed by pem-
brolizumab was shown to be well tolerated with accept-
able toxicity in patients with metastatic solid tumors [17]. 
Up-regulated genes post-SBRT are enriched by pathways 
analysis for innate and adaptive immunity and DNA 
damage response regulation. Large partially irradiated 
tumors exhibit control similar to smaller completely irra-
diated tumors.
The first STING agonists are being tested but may 
require novel approaches to overcome intratumoral 
delivery. BMS-986301 is a more potent STING agonist 
for which intramuscular administration may be possible 
[59] while SB-11285 may allow intravenous or tumor-
targeted STING agonism. Systemic inhibition of phos-
phodiesterase ENPP1 may decrease the threshold for 
STING agonism and TREX1 inhibitor administered via 
an infectious vector may offer a systemic indirect STING 
agonism approach. Tumor-targeted or systemic STING 
agonism may be the ideal partner for combination cancer 
therapeutic development.
Key points
• Given that a T cell-inflamed TME may serve as a pre-
dictive biomarker for response to immunotherapies, 
how do we treat non-T cell-infiltrated tumors?
• STING agonists may provide a means to deliberately 
initiate innate immune inflammation to promote an 
endogenous T cell response in non-T cell-inflamed 
tumors.
• Intratumoral administration of the STING agonist, 
MK-1454, resulted in complete tumor regression and 
enhances the efficacy of anti-PD-1 therapy in mouse 
syngeneic models and showed encouraging effi-
cacy and an acceptable safety profile in combination 
with pembrolizumab in patients with advanced solid 
tumors or lymphoma.
• Tumor-targeted or systemic STING agonism may be 
the ideal partner for combination cancer therapeutic 
development.
Conclusions
Since 2011, the use of novel immunotherapies and tar-
geted agents have significantly improved outcomes for 
patients with advanced melanoma. The challenge for the 
IO field is to achieve even greater improvements through 
optimizing treatment regimens, which increasingly 
involve drug combinations. Importantly, development of 
biomarkers that allow for selection of patients that will 
benefit from treatment through better understanding of 
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the interaction of the tumor and immune response is a 
critical need. The advent of new and improved standards 
of care is likely to continue and further enhance the long 
term survival of patients. Specifically, the use of immune 
checkpoint inhibitors and MAPK inhibitors is expand-
ing from the metastatic setting to encompass adjuvant as 
well as neo-adjuvant therapies, with increasing evidence 
of benefits in these populations.
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